Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Mengyi Lao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3650-5345; OpenAlex author ID A5056443773, A5153683103. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 12

  1. Corrigendum to Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci211838↗
  2. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Co-author DOI 10.1002/cac2.70038↗
  3. Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63146-2↗
  4. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci187024↗
  5. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. First author DOI 10.1080/15548627.2023.2300913↗
  6. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Co-author DOI 10.1016/j.ymthe.2023.07.021↗
  7. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Co-author DOI 10.1038/s41418-022-01102-z↗
  8. Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer. Co-author DOI 10.3390/cancers15082225↗
  9. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, rand… Co-author DOI 10.1186/s12885-022-09974-7↗
  10. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Co-author DOI 10.1038/s41388-021-01763-z↗
  11. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Co-author DOI 10.1038/s41467-021-24769-3↗
  12. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. Co-author DOI 10.1002/jmri.27024↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueli Bai · 11 shared papers, 2020–2025 · strength 1.70
  2. Tingbo Liang · 10 shared papers, 2020–2025 · strength 1.48
  3. Xiaozhen Zhang · 9 shared papers, 2020–2025 · strength 1.39
  4. Hanshen Yang · 8 shared papers, 2021–2025 · strength 1.36
  5. Lihong He · 7 shared papers, 2023–2025 · strength 1.24
  6. Kang Sun · 7 shared papers, 2023–2026 · strength 1.23
  7. Xiongbin Lu · 3 shared papers, 2025–2026 · strength 0.55
  8. Jian Xu · 4 shared papers, 2021–2024 · strength 0.55
  9. Xiao Zhi · 2 shared papers, 2025–2026 · strength 0.37
  10. Mao Ye · 2 shared papers, 2025–2026 · strength 0.37
  11. Jinyuan Song · 2 shared papers, 2025–2026 · strength 0.37
  12. Lingyue Liu · 2 shared papers, 2025 · strength 0.36
  13. Yan Chen · 2 shared papers, 2023–2025 · strength 0.34
  14. Yi Duan · 2 shared papers, 2021–2023 · strength 0.27
  15. Risheng Que · 2 shared papers, 2020–2022 · strength 0.23
  16. Wei Chen · 2 shared papers, 2020–2022 · strength 0.23
  17. Daqian Xu · 1 shared paper, 2025 · strength 0.22
  18. Tingbo Liang · 1 shared paper, 2025 · strength 0.22
  19. Tianyu Tang · 2 shared papers, 2020–2021 · strength 0.21
  20. Tingbo Liang · 1 shared paper, 2026 · strength 0.20
  21. Junming Huang · 1 shared paper, 2025 · strength 0.19
  22. Xinyuan Liu · 1 shared paper, 2025 · strength 0.19
  23. Xiang Li Ma · 1 shared paper, 2025 · strength 0.17
  24. Bingfeng Huang · 1 shared paper, 2022 · strength 0.14
  25. Tao Ma · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.